Description

Chromosomal translocations resulting in specific fusion genes are a hallmark of the leukemias. AML/ETO is a common recurrent translocation in childhood leukemia (10-20% overall). Similarly, the Philadelphia translocation results in a fused BCR/ABL gene and is found in 2-10% of pediatric leukemia presentations. The Oncology Fusion Transcripts BCR/ABL - AML/ETO (qPCR) Kit enables determination of these two common chromosome abnormalities in a single assay. This kit targets specific chimeric RNA transcripts produced from the fused genes. Results are obtained for each targeted fusion transcript independently. The test also includes an internal control for verification of assay performance.

Assay Overview

This assay is intended for use on cDNA synthesized from total RNA extracted from a whole blood sample. Following cDNA preparation using abm’s EasyScript Plus cDNA Synthesis Kit (provided in the kit), the sample cDNA is added to the pre-loaded 0.2ml qPCR reaction tube and thermocycled according to supplied parameters on a real-time PCR machine with optical monitoring of 495/520nM, 524/557nM, and 575/602nM (excitation/ emission) channels. The presence or absences of AML/ETO or BCR/ABL fusion transcripts are indicated by qPCR amplification.

Application

• Ease of use – includes cDNA preparation kit and pre-loaded reagent strips for fusion detection using qPCR.
• Simple interpretation with internal control for qPCR – verifies cDNA quality and successful qPCR amplification.
• Less than two hours from sample preparation to results
• Includes External Positive Control material for validation of kit and qPCR processes (post reverse transcription).

Disclaimer

1) This product is developed and intended for research use only. abm is not liable for any repercussions arising from the use of its assay kit(s) in the therapeutic application. 2) Individual assay performance is determined and specified based on abm’s standardized testing on a range of relevant control material, as defined for each particular assay. It is the responsibility of end users to validate these tests in their particular laboratory settings and protocols to a level appropriate to the user’s application.